20^th European Dermatology Congress April 29-30, 2020 Prague, Czech Republic

Biography:

Dr. Ofir Aharon, CEO and Founder of Patternox Ltd, inventor of PatScope Scanner. Ph.D. in electro-optics engineering, specializing in the field of computational electromagnetism. Worked at the GSI, the particle accelerator in Darmstadt, Germany. Ofir was part of a research team at the CTO Department of Elbit systems, and later had a position at the Advance Development Group as part of the CTO of KLA-Tencor USA. He is also the inventor of optical devices such as the DOSI scanner. He was Meopta’s representative and mediator in Samsung’s CTO and LG’s CTO-Korea headquarters.

Abstract:

PatScope by Patternox ltd. is a novel approach to detecting potential or actual melanoma that has proven highly effective in clinical trials. The technology identifies undetectable lesion distortions, not fully identified today by dermoscopy and provides an indication to the degree of lesion distortion and the possibility of it being cancerous.  Using PatScope Dr. Aharon achieved very high Sensitivity and Specificity. One can only imagine how beneficial Pat Scope can be in the hands of a trained dermatologist. 

In clinical tests, using Dr. Aharon’s method, it was identified that all lesions proven malignant by histology, including lesions that were clinically & dermoscopically diagnosed as benign by the medical staff.  Pat Scope’s technology enables the detection of tissue structure distortions of skin lesions even with non-pigmented lesions. Such distortions can indicate early stages of skin cancers like Melanoma, BCC and SCC, and early/effective detection results in reduced mortality rate, prevention of unnecessary surgeries and avoiding unnecessary scarring and costs.

 

Biography:

John M. Armstrong is the Head of Discovery for Galderma’s Prescription business. With a PhD in immunology and post-doctoral fellowships in personalized medicine and signal transduction pathways, he has 33 years of experience in immunology. His experience includes Medical Affairs activities in big pharma and running a personalized medicine company for many years. In his current role, Dr. Armstrong oversees the teams and talents from both Research and Business Development, with the purpose of exploring, discovering, and developing internal innovation, as well as exploring, forming, and managing alliances that bring external innovation into Galderma’s prescription pipeline and product portfolio.

Abstract:

Large biotech companies with a dermatology department generally harbor skills in large molecule development (i.e., monoclonal antibodies / mAbs) but never meet more than 20% of practicing dermatologists globally as a result. In contrast and by nature, dermatology start-up companies come to life with a product or products generated from a unique technology base that reflects either mAb or small molecular entity (SME) expertise; they may succeed by being acquired or by taking a long time to evolve.  Historically, legacy pure dermatology players have started with similar limitations, but staying competitive has required them to add a new technology capability to their in-house expertise through either time- and resource-consuming FTE growth or M&A activity, and there are few such legacy derm companies remaining in the world. At Galderma, we have developed a new model for conducting dermatology research – one that allows us to: 1)  address any unmet medical need with the most suitable technology required without waiting to grow in-house expertise or finance M&A; 2) double the resources we can invest in new projects; and 3) maintain our service to dermatologists throughout the world – whether they focus on mild disorders or the most severe, life-threatening diseases known in dermatology. In a world where disease knowledge and technology development are evolving at a pace at which others struggle to keep up, Galderma has found a way to ensure that the manufacturer need never be the rate-limiting step in bringing leading edge solutions to the prevention, treatment, or cure of dermatologic disorders.

 

Biography:

Published more than 120 papers in refereed journals and is serving as an editorial board member of various reputable journals.

 

Abstract:

The incidence of skin cancer is higher than all other cancers combined and the rate of skin cancer is increasing more than any of the top ten cancers in man.  Dermatologists, surgeons, oncologists and radiotherapists usually jointly manage skin cancers.  The strengths and limitations of the established procedures are known.  The cost for bringing a new anticancer drug to the market is about US$1B.  This translates to the ranking of anticancer drugs as the first of global spending by therapeutic class, this is a challenge for the health care system and for those affected by cancer.

Curaderm, a naturally derived topical cream for the treatment of skin cancer, has over the last decades modestly shown to be a very safe and effective treatment with many more strengths than limitations when compared to other skin cancer therapies.  Curaderm contains a class of antineoplastic glycoalkaloids, known as solasodine rhamnosides (BEC).  This review presents the developmental stages of Research, Preclinical and Clinical (Phases I to IV) of the topical cream Curaderm.  Cytotoxic BEC drugs offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance, convenience and affordability in the treatment of patients with skin cancer.